



Title	Pyridoxine supplementation during oocyte maturation improves the development and quality of bovine preimplantation embryos
Author(s)	Aboelenain, Mansour; Balboula, Ahmed Zaky; Kawahara, Manabu; Montaser, Abd El-Monem; Zaabel, Samy Moawad; Kim, Sung-Woo; Nagano, Masashi; Takahashi, Masashi
Citation	Theriogenology, 91, 127-133 <a href="https://doi.org/10.1016/j.theriogenology.2016.12.022">https://doi.org/10.1016/j.theriogenology.2016.12.022</a>
Issue Date	2017-03-15
Doc URL	<a href="http://hdl.handle.net/2115/67967">http://hdl.handle.net/2115/67967</a>
Rights	© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Rights(URL)	<a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Type	article (author version)
File Information	Theriogenology proof.pdf



[Instructions for use](#)

1 **Pyridoxine supplementation during oocyte maturation improves the development**  
2 **and quality of bovine preimplantation embryos**

3

4 **Mansour Aboelenain<sup>a,b</sup>, Ahmed Zaky Balboula<sup>a,b</sup>, Manabu Kawahara<sup>a</sup>, Abd El-Monem**  
5 **Montasser<sup>b</sup>, Samy Moawad Zaabel<sup>b</sup>, Sung-Woo Kim<sup>c</sup>, Masashi Nagano<sup>d</sup>, Masashi**  
6 **Takahashi<sup>a,\*</sup>**

7 <sup>a</sup> *Laboratory of Animal Breeding and Reproduction, Department of Animal Science, Graduate*  
8 *school of Agriculture, Hokkaido University, Hokkaido, 060-8589, Japan*

9 <sup>b</sup> *Department of Theriogenology, Faculty of Veterinary Medicine, Mansoura University,*  
10 *Mansoura, 35516, Egypt*

11 <sup>c</sup> *National Institute of Animal Science, Animal Genetic Resources Research Center, Namwon, ,*  
12 *55717, South Korea.*

13 <sup>d</sup> *Laboratory of Theriogenology, Department of Veterinary Clinical Sciences, Graduate School*  
14 *of Veterinary Medicine, Hokkaido University, Hokkaido, 060-0818, Japan.*

15

16 Running title: Effect of pyridoxine supplementation during oocytes maturation.

17

18 <sup>\*</sup>Corresponding author: Masashi Takahashi, Laboratory of Animal Breeding and Reproduction,  
19 Department of Animal Science, Graduate school of Agriculture, Hokkaido University

20 Telephone: +81-11-706-2542

21 Fax: +81-11-706-2542

22 Email: [mmasashi@anim.agr.hokudai.ac.jp](mailto:mmasashi@anim.agr.hokudai.ac.jp)

23 **Abstract.**

24 Recently, inhibition of cathepsin B (CTSB) activity during in vitro maturation (IVM) and culture  
25 (IVC) improved the developmental competence and quality of bovine oocytes and embryos. E-  
26 64 is a widely used inhibitor to inhibit CTSB activity, however, E-64 inhibits not only CTSB  
27 activity but also the activities of other proteases including cathepsin L (CTSL), papain, calpain,  
28 and trypsin. Pyridoxine, the catalytically active form of vitamin B6, plays a crucial role in  
29 several cellular processes and has the ability to inhibit CTSB activity. However, whether  
30 pyridoxine has an improving effect during IVM of bovine oocytes is still unknown. In this study,  
31 we investigated the effect of pyridoxine supplementation during IVM on the developmental  
32 competence of bovine oocytes and the quality of the produced blastocysts. Supplementation of  
33 pyridoxine to the maturation medium significantly decreased the activity of CTSB in both bovine  
34 cumulus cells and oocytes. Moreover, pyridoxine improved both the blastocyst and hatched  
35 blastocyst rates. In addition, the presence of pyridoxine during IVM also significantly improved  
36 the quality of the produced embryos by increasing the total cell number as well as decreasing the  
37 CTSB mRNA expression and apoptotic rate. These results indicate that pyridoxine is a promising  
38 tool to improve the developmental competence of bovine oocytes and subsequent embryo  
39 quality.

40 **Keywords:** cathepsin B, pyridoxine, in vitro maturation, developmental competence, bovine  
41 oocytes

42

43

44

## 45 **1. Introduction**

46

47 Many studies have been performed to improve the developmental competence of bovine  
48 oocytes and embryos [1-4]. However, the quality of *in vitro* produced (IVP) embryos remains  
49 incomparable to that of *in vivo* produced embryos [5-7]. Many stressors during *in vitro*  
50 maturation (IVM), either extrinsic such as medium composition or culture conditions, or intrinsic  
51 such as oocyte quality itself, affect the developmental competence and quality of IVP embryos  
52 [8, 9]. As a result, it is necessary to find optimal conditions to overcome the negative factors  
53 affecting the developmental competence of bovine oocytes.

54 Cathepsin B (CTSB) is an abundant and ubiquitously expressed cysteine protease found in a  
55 wide variety of cells, including bovine oocytes and cumulus cells [10, 11]. CTSB is involved in  
56 many physiological processes, including intracellular protein degradation in lysosomes, initiation  
57 of the apoptotic pathway [12, 13], stress-induced response [14], autophagy [15], and  
58 differentiation of cancer cells [16]. We have shown that CTSB activity is inversely correlated  
59 with the quality and developmental competence of bovine oocytes [3, 10]. Thus, inhibiting  
60 CTSB activity during *in vitro* maturation (IVM) has emerged as a new strategy to improve the  
61 developmental competence of bovine oocytes *in vitro* [10].

62 l-trans-Epoxysuccinyl-Leucylamido-(4-guanidino) Butane (E-64) and its derivative  
63 compounds (CA-030 and CA-074) are the most commonly used inhibitors to inhibit CTSB  
64 activity [17, 18]. Unfortunately, the affinity of E-64 to bind an active thiol group in many  
65 cysteine proteases renders it a non-selective CTSB inhibitor [19]. In fact, it can also inhibit many  
66 cysteine proteases including CTSL, papain, calpain, as well as trypsin [20]. In addition,  
67 application of oral administration of E-64 has been achieved for protection from bacterial and

68 viral infections [21-23], that raises the possible improvement of oocyte quality by *in vivo*  
69 administration of CTSB inhibitor. However, large scale application of CTSB inhibitor such as *in*  
70 *vivo* administration is impractical because of the cost and the possible toxicity. Thus, it is  
71 necessary to find a natural alternative inhibitor that could be used to regulate CTSB activity in  
72 mammalian oocytes either *in vivo* or *in vitro*.

73 Vitamin B<sub>6</sub> coenzymes such as pyridoxine is very similar to vitamin B<sub>6</sub> enzyme in terms of  
74 amino acid metabolism and synthesis of nucleic acids [24]. Vitamin B<sub>6</sub> has an essential role in  
75 antioxidant activities [25]. Singlet oxygen resistance 1 (*SOR 1*) is involved in *de novo* vitamin B<sub>6</sub>  
76 biosynthesis. Pyridoxine quenches singlet oxygen at a rate comparable to that of vitamin C and  
77 E, two of the most highly efficient biological antioxidants [26]. Interestingly, vitamin B<sub>6</sub>  
78 coenzyme has an active aldehyde at position 4 of the pyridine ring, which has a binding affinity  
79 for the active SH-site of cysteine residues in CTSB. This unique structure can explain the  
80 inhibitory effect of pyridoxine on CTSB activity in helper T lymphocyte type-2 [27]. Using  
81 pyridoxine as a CTSB inhibitor outperforms others by its natural origin from whole-grain  
82 products (including cereals), starchy vegetables, fish, liver and organ meats [28, 29]. In this  
83 study, we investigated the effect of pyridoxine on CTSB activity during oocyte maturation, and  
84 its effect on the subsequent development and quality of embryos.

85

86

87

88

## 89 2. Material and Methods

90

### 91 2.1. Oocyte collection and IVM

92 According to the strict regulation of Sapporo slaughterhouse and after BSE screening test  
93 result, bovine ovaries were brought to our laboratory from a local abattoir within 12 h after  
94 slaughter. The ovaries were washed several times in a sterile saline. IVM was performed as  
95 described previously [30]. In brief, cumulus–oocyte complexes (COCs) were aspirated from  
96 follicles (2–8 mm in diameter) using an 18-gauge needle attached to a 10-ml syringe and washed  
97 three times in tissue culture medium (TCM)-199 medium (Invitrogen, Grand Island, NY, USA).  
98 Ten COCs were matured in a 50- $\mu$ l drop of TCM-199 supplemented with 10% fetal calf serum  
99 (FCS; Invitrogen), follicle stimulating hormone (FSH; 0.02 units/ml; Kyoritsu Seiyaku Corp.,  
100 Tokyo, Japan), estradiol-17 $\beta$  (1  $\mu$ g/ml; Sigma-Aldrich, St. Louis, MO, USA), and gentamycin  
101 (50  $\mu$ g/ml; Sigma-Aldrich) covered with mineral oil (Sigma-Aldrich) for 22–24 h at 38.5 °C in a  
102 humidified atmosphere of 5% CO<sub>2</sub> in air.

103

### 104 2.2. In vitro fertilization (IVF)

105 IVF was conducted according to a procedure described previously [31]. Briefly, after  
106 thawing of frozen semen in warm water (37 °C) for 20 sec, motile sperm were separated using  
107 percoll gradients (45 and 90%) (Sigma-Aldrich). COCs were co-incubated with motile sperm (5  
108  $\times 10^6$  cells/ml) in droplets (10 COCs/100  $\mu$ l) of modified Brackett and Oliphant's isotonic  
109 medium containing 3 mg/ml fatty acid-free bovine serum albumin (BSA) (Sigma-Aldrich) and  
110 2.5 mM theophylline for 18 h at 38.5 °C under a humidified atmosphere of 5% CO<sub>2</sub>, and 90% N<sub>2</sub>.

111

112 2.3. *In vitro culture (IVC)*

113 IVC of presumptive zygotes was performed as described previously [32]. Briefly, after  
114 fertilization, cumulus cells were removed by mechanical pipetting (internal diameter of the  
115 pipette, 150–180 mm) [33], and the presumptive zygotes were transferred to 50 µl drops (20–30  
116 zygotes/drop) [34] of modified synthetic oviduct fluid (SOF) medium supplemented with amino  
117 acid solution (Sigma-Aldrich), 10 µl/ml insulin, 1 mM glucose, and 3 mg/ml fatty acid-free BSA  
118 at 38.5 °C under 5% CO<sub>2</sub>, 5% O<sub>2</sub> and 90% N<sub>2</sub>.

119

120 2.4. *RNA isolation and quantitative reverse transcription-PCR (qRT-PCR)*

121 Total RNA from twenty blastocysts per replication was extracted using ReliaPrep RNA Cell  
122 Miniprep System (Promega, Madison, WI, USA) according to the manufacturer's instructions.  
123 The extracted RNA was then immediately used for RT-PCR or stored at -80 °C until analysis.  
124 cDNA was synthesized with the ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan).  
125 Conventional PCR was performed using the GoTaq Hot Start Green Master Mix (Promega,  
126 Madison, WI, USA). Primers specific for *CTSB* were designed and commercially synthesized  
127 (Eurofins Genomics, Co., Ltd., Tokyo, Japan). The primer information is presented in Table 1.  
128 The reactions were carried out in 96-well PCR plates, in a total volume of 10 µl containing 1 µl  
129 of 10 pmol/µl of each primer, 5 µl of the Thunderbird Sybr qPCR Mix (Toyobo), and 3 µl of  
130 cDNA. After centrifugation, the plates were placed in a Roche Light Cycler 480 II (Roche,  
131 Basel, Switzerland) and subjected to the following cycling conditions: a denaturation step at 95  
132 °C for 30 sec, an amplification step of 50 cycles at 95 °C for 10 sec, 57 °C for 15 sec, 72 °C for  
133 30 sec, a melting-curve step using a gradient of 55–95 °C with an increment of 2.2 °C/sec and  
134 continuous fluorescence acquisition, and a cooling step at 4 °C. Amplicons that consisted of PCR

135 products were confirmed to have a single band for each target gene by electrophoresis and  
136 sequenced to verify their authenticity. The expression levels of the target genes were determined  
137 relative to that of the histone H2A family member Z (*H2AFZ*) [35].

138

### 139 *2.5. Detection of CTSB activity*

140 CTSB activity was measured by using Magic Red Detection Kit (MR-RR) 2  
141 (Immunochemistry Technologies, LLC, Minneapolis, MN, USA) according to the  
142 manufacturer's protocol. Briefly, IVM oocytes or COCs were stained in 250  $\mu$ l of serum-free  
143 Dulbecco's modified Eagle medium (DMEM) containing 1  $\mu$ l of reaction mix in a humidified  
144 atmosphere of 5% CO<sub>2</sub> at 38.5 °C for 30 min. For nuclei staining, Hoechst (H 33342; Sigma-  
145 Aldrich) was added and incubated in the same culture conditions for 5 min. After rinsing in  
146 phosphate-buffered saline (PBS), the stained oocytes or COCs were mounted onto a glass slide  
147 and observed under a fluorescence microscope BZ-9000 Bioevo (Keyence, Osaka, Japan). An  
148 excitation filter of 590 nm was used for CTSB detection (red), while an excitation filter of 365  
149 nm was used for observing the cumulus cell nuclei (blue).

150

### 151 *2.6. Differential staining*

152 Differential staining for bovine embryos was carried out as described previously [36]. In  
153 brief, blastocysts were incubated at room temperature for 40–60 sec in 0.2% (v/v) Triton-X100  
154 with 0.1 mg/ml propidium iodide (P4864; Sigma-Aldrich). Blastocysts were then stained with 25  
155  $\mu$ g/ml of Hoechst reagent (Sigma-Aldrich) in 100% (w/v) EtOH at 4°C for 3 h. The stained  
156 blastocysts were rinsed in glycerol, mounted onto a glass slide, and observed with a fluorescence



157 microscope (Nikon, Tokyo, Japan). The nuclei of the inner cell mass (ICM) were stained in blue  
158 by Hoechst reagent and the nuclei of trophoctoderm (TE) cells were stained in pink by both  
159 Hoechst reagent and propidium iodide.

160

## 161 *2.7. Apoptosis analysis*

162 A Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) assay kit  
163 was used to assess the presence of apoptotic cells (In Situ Cell Death Detection Kit; Roche) in  
164 day 8 blastocysts, as described previously [10] with some modifications. In brief, blastocysts  
165 were fixed in 4% (w/v) paraformaldehyde solution for 15–30 min. After rinsing 4 times in PBS,  
166 blastocysts were permeabilized in PBS with 0.2% Triton-X and 0.2% polyvinylalcohol (PVA)  
167 for 20 min. Blastocysts were then washed thrice in PBS with 0.1% Triton-X and 0.3% BSA for  
168 10 min. The fragmented DNA ends were labeled with fluorescein-dUTP for 60 min at 37°C.  
169 After incubation, the blastocysts were washed thrice in PBS with 0.2% PVA for 10 min each,  
170 followed by mounting onto glass slides using mounting solution (Vectashield with DAPI, Vector  
171 Laboratories, Burlingame, CA, USA). The fluorescence of fragmented DNA was detected by  
172 using a fluorescence microscope BZ-9000 Bioevo (Keyence) and 450-500-nm excitation filter.

## 173 *2.8. Experimental design*

174 *Experiment 1: Effect of pyridoxine during IVM on CTSB activity of COCs and oocytes*

175 To investigate the inhibitory effect of Pyridoxine HCL (Sigma–Aldrich) on CTSB, CTSB  
176 activity was examined in bovine COCs and oocytes matured in TCM-199 with or without 250  
177 µM (prepared in PBS) pyridoxine for 24 h. The concentration of pyridoxine was selected based  
178 on a previous study [24]. After maturation, both COCs and denuded oocytes were evaluated for

179 CTSB activity using Magic Red Detection Kit. Denuded oocytes were obtained by mechanical  
180 removal of cumulus cells in PBS supplemented with 0.1% (W/V) hyaluronidase (H3506; Sigma-  
181 Aldrich).

182 *Experiment 2: Effect of pyridoxine supplementation during IVM on developmental competence*  
183 *of bovine oocytes*

184 Pyridoxine (250  $\mu$ M) was added to the maturation medium to assess its effect on the subsequent  
185 developmental competence of oocytes. After 24 h of maturation, matured COCs were fertilized  
186 and cultured at 38.5°C in a humidified atmosphere of 5% CO<sub>2</sub> in air. Developmental competence  
187 was assessed by calculating the cleavage and blastocyst formation rates on days 2 and 8,  
188 respectively. In addition, the hatched rate was also calculated for day 8 blastocysts.

189 *Experiment 3: Effect of pyridoxine supplementation during IVM on the quality of day 8*  
190 *blastocysts*

191 After COCs maturation with or without 250  $\mu$ M pyridoxine, COCs were fertilized and cultured  
192 for 8 days. The quality of day 8 blastocysts was evaluated using total cell number, differential  
193 staining, TUNEL staining, and *CSTB* gene expression.

## 194 *2.9. Statistical analysis*

195 Each experiment was performed at least three times, and the data are expressed as the means  
196  $\pm$  standard error of the mean (SEM). The statistical significance was analyzed by Student's *t*-  
197 tests. Non-parametric Mann-Whitney's test was also employed to confirm the significance. Data  
198 for cleavage and blastocyst rates were analyzed by one-way ANOVA with Fisher protected least  
199 significant difference using the SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA);  $P <$   
200 0.05 was considered statistically significant.

## 201 **3. Results**

202

### 203 **3.1. Effect of pyridoxine on CTSB activity in IVM COCs and oocytes**

204

205 To confirm the inhibitory effect of pyridoxine on CTSB activity in bovine oocytes and  
206 cumulus cells, COCs were cultured with or without 250  $\mu$ M pyridoxine for 24 h followed by  
207 detection of CTSB activity. CTSB activity was clearly decreased in the cumulus cells of IVM  
208 COCs matured with 250  $\mu$ M pyridoxine (Fig. 1B,D) compared with those matured without  
209 pyridoxine (Fig. 1A,C). Quantification of the fluorescence intensity corresponding to CTSB  
210 activity indicated a significant decrease in pyridoxine-treated COCs when compared with that of  
211 control COCs (Fig. 1E). In addition, CTSB activity was significantly lower in denuded oocytes  
212 matured with 250  $\mu$ M pyridoxine (Fig. 1G,H) than denuded oocytes matured in pyridoxine-free  
213 medium (Fig. 1F, H).

214

### 215 **3.2. Effect of pyridoxine supplementation during IVM on the developmental competence of** 216 **bovine oocytes**

217

218 Different concentrations (0, 100, 250, and 500  $\mu$ M) of pyridoxine were added to the IVM  
219 medium and both cleavage and blastocyst formation rates were evaluated on days 2 and 8,  
220 respectively. Although cleavage rate did not differ significantly among treated groups, the  
221 highest blastocyst formation rate was observed in the presence of 250  $\mu$ M of pyridoxine (Fig.  
222 S1). Therefore, pyridoxine concentration of 250  $\mu$ M was selected for further evaluation.

223 Interestingly, addition of 250  $\mu$ M pyridoxine to the maturation medium increased the blastocyst  
224 formation rate and the percentage of hatched blastocysts significantly (Table 2).

225

### 226 **3.3. Effect of pyridoxine supplementation during IVM on the quality of blastocysts**

227

228 The quality of preimplantation embryos could be evaluated using many parameters including  
229 the total cell number, the number of trophoctoderm cells and the apoptotic rate. The results of  
230 differential staining showed that pyridoxine significantly increased the number of both total cells  
231 and trophectoderm cells of day 8 blastocysts when compared with the control group (Table 3).  
232 Importantly, the percentage of TUNEL-positive cells in blastocysts derived from COCs matured  
233 with pyridoxine was significantly lower than that in the control group (Fig. 2A,C). Consistent  
234 with this result, *CTSB* expression was decreased significantly in blastocysts obtained from  
235 pyridoxine-supplemented COCs than that of the control group (Fig. 2B,D).

236

## 237 **4. Discussion**

238

239 Our results showed that pyridoxine is an efficient tool to inhibit *CTSB* activity in bovine  
240 COCs and oocytes. Moreover, supplementation of pyridoxine during IVM improved the  
241 developmental competence and quality of the produced blastocysts. These results suggest a  
242 promising role of pyridoxine in improving the efficiency of *in vitro* embryo production.

243 Pyridoxine inhibits *CTSB* activity in helper T lymphocyte type-2 [27]. This finding is in  
244 agreement with our results showing that pyridoxine inhibits *CTSB* activity in bovine oocytes.  
245 This inhibitory effect of pyridoxine on *CTSB* might be attributed to the presence of active

246 aldehydes at position 4 of the pyridine ring. Such unique structure is critical to inhibit CTSSB  
247 activity by its affinity for the active SH-site of CTSSB forming irreversible thiosemiacetal bonds  
248 [24]. In addition, vitamin B<sub>6</sub> has also antioxidant activities [25]. *SOR 1* showed that pyridoxine  
249 quenches singlet oxygen at a rate comparable to those of vitamin C and E, two of the most highly  
250 efficient biological antioxidants [26]. However, the possible effect of pyridoxine on the  
251 developmental competence of mammalian oocytes was unknown.

252 CTSSB inhibition emerged as a new approach to improve the developmental competence of  
253 bovine oocytes and preimplantation embryos [3, 10, 37]. Although the developmental  
254 competence of control oocytes was relatively low, most likely due to the unavoidable delay of  
255 ovary retrieval from the slaughterhouse, addition of pyridoxine to the IVM medium significantly  
256 improved the developmental competence of bovine oocytes by increasing the blastocyst rate. The  
257 average total cell number and the percentage of TUNEL positive cells can be used as markers for  
258 evaluating the quality of preimplantation embryos [36]. Addition of pyridoxine to the IVM  
259 medium increased the number of trophectoderm cells and the total cell number of day 8  
260 blastocysts and decreased the apoptotic rate. We previously demonstrated that CTSSB activity is  
261 inversely correlated with the quality of bovine embryos and, thus, can be used as an indicator of  
262 embryo quality [3, 38]. Our data showed that addition of pyridoxine to the IVM medium  
263 significantly decreased *CTSSB* mRNA expression in the produced blastocysts. Collectively, these  
264 results indicate that pyridoxine is a novel component to enhance the developmental competence  
265 of bovine oocytes and the quality of their blastocysts.

266 Our observation of improved developmental competence of pyridoxine-treated oocytes is  
267 consistent with the results obtained with E-64, another CTSSB inhibitor. Addition of E-64 to the  
268 IVM medium significantly improved the developmental competence of bovine oocytes [10, 11]

269 and the quality of the produced embryos [3]. Although E-64 has beneficial effect on  
270 developmental competence of bovine oocytes, it has been known to inhibit several types of  
271 cysteine proteases including CTSL papain, calpain, and trypsin [20]. On the other hand, to our  
272 knowledge, pyridoxine does not have the ability to inhibit these proteases. Taken together, this  
273 observation suggests that both inhibitors improved the developmental competence of bovine  
274 oocytes by inhibiting CTSB activity, but not through inhibiting other proteases. Furthermore, the  
275 similar effects of pyridoxine and E-64 on oocyte developmental competence and subsequent  
276 quality supports the hypothesis that pyridoxine is an effective inhibitor of CTSB activity and  
277 provides further evidence that inhibiting CTSB activity is a promising approach to improve the  
278 developmental competence of bovine oocytes.

279 The beneficial effect of pyridoxine on the developmental competence of oocytes might be  
280 attributed to its effect on inhibiting CTSB-induced apoptosis pathway. Apoptosis has been  
281 shown to be induced by proteases such as CTSB that leaked from lysosomes partially damaged  
282 by moderate stress [9, 39]. CTSB leakage can initiate apoptosis by activating initiator caspases  
283 and executioner caspases [40]. The significant decrease the rate of TUNEL-positive cells and  
284 *CTSB* transcript abundance in blastocysts produced from pyridoxine-treated oocytes, suggests  
285 that pyridoxine improved the developmental competence of bovine oocytes by inhibiting CTSB,  
286 which in turn, perturbed the apoptotic pathway. However, further investigations are required to  
287 elucidate whether pyridoxine has another pathway to promote the developmental competence of  
288 bovine oocytes.

289 Pyridoxine has been used to treat diseases including adult-onset clinical conditions [29] and  
290 carpal tunnel syndrome [41]. Importantly, although no data for developmental competence and  
291 quality of oocytes, pyridoxine was used as a maternal dietary supplement to affect gene

292 expression patterns of *in vivo* derived porcine blastocysts [42]. In addition, pyridoxine could be  
293 used to treat nausea and vomiting during pregnancy in women [29, 43]. Taken together, the  
294 natural and nontoxic properties of pyridoxine make it an important candidate as a natural drug to  
295 improve the developmental competence and the quality of embryos by inhibiting CTSB *in vivo*.

296 In conclusion, our results show that 1) pyridoxine can inhibit CTSB activity during oocyte  
297 maturation and 2) addition of pyridoxine to the IVM medium is a promising tool to enhance the  
298 developmental competence of bovine oocytes and the quality of their embryos.

299

## 300 **5. Declaration of interest**

301 The authors declare that there is no conflict of interest that could be perceived as prejudicing  
302 the impartiality of the research reported.

303

## 304 **6. Submission declaration**

305 The authors declare that the work described above has not been published previously, that it is  
306 not under consideration for publication elsewhere, that its publication is approved by all authors and  
307 tacitly or explicitly by the responsible authorities where the work was carried out, and that, if  
308 accepted, it will not be published elsewhere including electronically in the same form, in English or  
309 in any other language, without the written consent of the copyright-holder.

310

## 311 **7. Funding & Acknowledgement**

312 This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for  
313 the Promotion of Science (KAKENHI, 15H04579) and by the Cooperative Research Program for  
314 Agriculture Science & Technology Development (RDA PJ01029305).

315

## 316 **8. References**

317 [1] Song BS, Kim JS, Kim CH, Han YM, Lee DS, Lee KK, et al. Prostacyclin stimulates  
318 embryonic development via regulation of the cAMP response element-binding protein-cyclo-  
319 oxygenase-2 signalling pathway in cattle. *Reproduction, fertility, and development.*  
320 2009;21:400-7.

321 [2] Song BS, Yoon SB, Kim JS, Sim BW, Kim YH, Cha JJ, et al. Induction of autophagy  
322 promotes preattachment development of bovine embryos by reducing endoplasmic reticulum  
323 stress. *Biology of reproduction.* 2012;87:8, 1-11.

324 [3] Balboula AZ, Yamanaka K, Sakatani M, Hegab AO, Zaabel SM, Takahashi M. Intracellular  
325 cathepsin B activity is inversely correlated with the quality and developmental competence of  
326 bovine preimplantation embryos. *Mol Reprod Dev.* 2010;77:1031-9.

327 [4] Yamanaka K, Balboula AZ, Sakatani M, Takahashi M. Gene silencing of DNA  
328 methyltransferases by RNA interference in bovine fibroblast cells. *The Journal of reproduction*  
329 *and development.* 2010;56:60-7.

330 [5] Lim KT, Jang G, Ko KH, Lee WW, Park HJ, Kim JJ, et al. Improved in vitro bovine embryo  
331 development and increased efficiency in producing viable calves using defined media.  
332 *Theriogenology.* 2007;67:293-302.

333 [6] Beaujean N. Epigenetics, embryo quality and developmental potential. *Reproduction,*  
334 *fertility, and development.* 2014;27:53-62.



335 [7] Ventura-Junca P, Irarrazaval I, Rolle AJ, Gutierrez JI, Moreno RD, Santos MJ. In vitro  
336 fertilization (IVF) in mammals: epigenetic and developmental alterations. Scientific and  
337 bioethical implications for IVF in humans. *Biological research*. 2015;48:68.

338 [8] Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. *Current opinion*  
339 *in cell biology*. 2006;18:444-52.

340 [9] Balboula AZ, Yamanaka K, Sakatani M, Kawahara M, Hegab AO, Zaabel SM, et al.  
341 Cathepsin B activity has a crucial role in the developmental competence of bovine cumulus-  
342 oocyte complexes exposed to heat shock during in vitro maturation. *Reproduction*.  
343 2013;146:407-17.

344 [10] Balboula AZ, Yamanaka K, Sakatani M, Hegab AO, Zaabel SM, Takahashi M. Cathepsin B  
345 activity is related to the quality of bovine cumulus oocyte complexes and its inhibition can  
346 improve their developmental competence. *Mol Reprod Dev*. 2010;77:439-48.

347 [11] Bettegowda A, Patel OV, Lee KB, Park KE, Salem M, Yao J, et al. Identification of novel  
348 bovine cumulus cell molecular markers predictive of oocyte competence: functional and  
349 diagnostic implications. *Biol Reprod*. 2008;79:301-9.

350 [12] Frlan R, Gobec S. Inhibitors of cathepsin B. *Current medicinal chemistry*. 2006;13:2309-27.

351 [13] Barrett AJ, Kirschke H. Cathepsin B, Cathepsin H, and cathepsin L. *Methods in*  
352 *enzymology*. 1981;80 Pt C:535-61.

353 [14] Johansson AC, Appelqvist H, Nilsson C, Kagedal K, Roberg K, Ollinger K. Regulation of  
354 apoptosis-associated lysosomal membrane permeabilization. *Apoptosis : an international journal*  
355 *on programmed cell death*. 2010;15:527-40.

356 [15] Lamparska-Przybysz M, Gajkowska B, Motyl T. Cathepsins and BID are involved in the  
357 molecular switch between apoptosis and autophagy in breast cancer MCF-7 cells exposed to

358 camptothecin. *Journal of physiology and pharmacology : an official journal of the Polish*  
359 *Physiological Society*. 2005;56 Suppl 3:159-79.

360 [16] Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, et al.  
361 Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. *Clinical &*  
362 *experimental metastasis*. 1997;15:368-81.

363 [17] Towatari T, Nikawa T, Murata M, Yokoo C, Tamai M, Hanada K, et al. Novel  
364 epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. *FEBS letters*.  
365 1991;280:311-5.

366 [18] Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, et al. Novel  
367 epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. *FEBS letters*.  
368 1991;280:307-10.

369 [19] Montaser M, Lalmanach G, Mach L. CA-074, but not its methyl ester CA-074Me, is a  
370 selective inhibitor of cathepsin B within living cells. *Biological chemistry*. 2002;383:1305-8.

371 [20] Katunuma N. Structure-based development of specific inhibitors for individual cathepsins  
372 and their medical applications. *Proceedings of the Japan Academy Series B, Physical and*  
373 *biological sciences*. 2011;87:29-39.

374 [21] Feng Y, Ni L, Wang Q. Administration of cathepsin B inhibitor CA-074Me reduces  
375 inflammation and apoptosis in polymyositis. *Journal of dermatological science*. 2013;72:158-67.

376 [22] Morimoto M, Tanabe F, Kasai H, Ito M. Effect of a thiol proteinase inhibitor, E-64-d, on  
377 susceptibility to infection with *Staphylococcus aureus* in Chediak-Higashi syndrome (beige)  
378 mice. *International immunopharmacology*. 2007;7:973-80.

379 [23] Ebina T, Tsukada K. Protease inhibitors prevent the development of human rotavirus-  
380 induced diarrhea in suckling mice. *Microbiology and immunology*. 1991;35:583-8.

381 [24] Katunuma N, Matsui A, Inubushi T, Murata E, Kakegawa H, Ohba Y, et al. Structure-based  
382 development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and  
383 in vivo. *Biochemical and biophysical research communications*. 2000;267:850-4.

384 [25] Endo N, Nishiyama K, Okabe M, Matsumoto M, Kanouchi H, Oka T. Vitamin B6  
385 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine and copper.  
386 *Biochimica et biophysica acta*. 2007;1770:571-7.

387 [26] Ehrenshaft M, Bilski P, Li MY, Chignell CF, Daub ME. A highly conserved sequence is a  
388 novel gene involved in de novo vitamin B6 biosynthesis. *Proceedings of the National Academy  
389 of Sciences of the United States of America*. 1999;96:9374-8.

390 [27] Katunuma N, Matsui A, Endo K, Hanba J, Sato A, Nakano M, et al. Inhibition of  
391 intracellular cathepsin activities and suppression of immune responses mediated by helper T  
392 lymphocyte type-2 by peroral or intraperitoneal administration of vitamin B6. *Biochemical and  
393 biophysical research communications*. 2000;272:151-5.

394 [28] Lindberg AS, Leklem JE, Miller LT. The effect of wheat bran on the bioavailability of  
395 vitamin B-6 in young men. *The Journal of nutrition*. 1983;113:2578-86.

396 [29] Stover PJ, Field MS. Vitamin B-6. *Advances in nutrition*. 2015;6:132-3.

397 [30] Takahashi Y, Hishinuma M, Matsui M, Tanaka H, Kanagawa H. Development of in vitro  
398 matured/fertilized bovine embryos in a chemically defined medium: influence of oxygen  
399 concentration in the gas atmosphere. *The Journal of veterinary medical science / the Japanese  
400 Society of Veterinary Science*. 1996;58:897-902.

401 [31] Kang SS, Ofuji S, Imai K, Huang W, Koyama K, Yanagawa Y, et al. The efficacy of the  
402 well of the well (WOW) culture system on development of bovine embryos in a small group and  
403 the effect of number of adjacent embryos on their development. *Zygote*. 2014:1-4.

404 [32] Takahashi Y, Kanagawa H. Effects of glutamine, glycine and taurine on the development of  
405 in vitro fertilized bovine zygotes in a chemically defined medium. *The Journal of veterinary*  
406 *medical science / the Japanese Society of Veterinary Science*. 1998;60:433-7.

407 [33] Aono A, Nagatomo H, Takuma T, Nonaka R, Ono Y, Wada Y, et al. Dynamics of  
408 intracellular phospholipid membrane organization during oocyte maturation and successful  
409 vitrification of immature oocytes retrieved by ovum pick-up in cattle. *Theriogenology*.  
410 2013;79:1146-52 e1.

411 [34] Matwee C, Kamaruddin M, Betts DH, Basrur PK, King WA. The effects of antibodies to  
412 heat shock protein 70 in fertilization and embryo development. *Molecular human reproduction*.  
413 2001;7:829-37.

414 [35] Nagatomo H, Kagawa S, Kishi Y, Takuma T, Sada A, Yamanaka K-i, et al. Transcriptional  
415 Wiring for Establishing Cell Lineage Specification at the Blastocyst Stage in Cattle. *Biology of*  
416 *reproduction*. 2013;88:158, 1-10.

417 [36] Fouladi-Nashta AA, Alberio R, Kafi M, Nicholas B, Campbell KH, Webb R. Differential  
418 staining combined with TUNEL labelling to detect apoptosis in preimplantation bovine embryos.  
419 *Reproductive biomedicine online*. 2005;10:497-502.

420 [37] Min SH, Song BS, Yeon JY, Kim JW, Bae JH, Park SY, et al. A cathepsin B inhibitor, E-  
421 64, improves the preimplantation development of bovine somatic cell nuclear transfer embryos.  
422 *The Journal of reproduction and development*. 2014;60:21-7.

423 [38] Aardema H, Lolicato F, van de Lest CH, Brouwers JF, Vaandrager AB, van Tol HT, et al.  
424 Bovine cumulus cells protect maturing oocytes from increased fatty acid levels by massive  
425 intracellular lipid storage. *Biology of reproduction*. 2013;88:164.

426 [39] Kim SH, Zhao MH, Liang S, Cui XS, Kim NH. Inhibition of cathepsin B activity reduces  
427 apoptosis by preventing cytochrome c release from mitochondria in porcine parthenotes. The  
428 Journal of reproduction and development. 2015;61:261-8.

429 [40] Vancompernelle K, Van Herreweghe F, Pynaert G, Van de Craen M, De Vos K, Totty N, et  
430 al. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity.  
431 FEBS letters. 1998;438:150-8.

432 [41] Aufiero E, Stitik TP, Foye PM, Chen B. Pyridoxine hydrochloride treatment of carpal tunnel  
433 syndrome: a review. Nutrition reviews. 2004;62:96-104.

434 [42] Dalto BD, Tsoi S, Audet I, Dyck MK, Foxcroft GR, Matte JJ. Gene expression of porcine  
435 blastocysts from gilts fed organic or inorganic selenium and pyridoxine. Reproduction.  
436 2015;149:31-42.

437 [43] Wibowo N, Purwosunu Y, Sekizawa A, Farina A, Tambunan V, Bardosono S. Vitamin B(6)  
438 supplementation in pregnant women with nausea and vomiting. International journal of  
439 gynaecology and obstetrics: the official organ of the International Federation of Gynaecology  
440 and Obstetrics. 2012;116:206-10.

#### 441 **Figure legends**

#### 442 **Figure 1: Pyridoxine inhibits CTSB activity in bovine oocytes.**

443 CTSB activity was higher in IVM COCs matured without 250  $\mu$ M pyridoxine (A) than that  
444 matured with pyridoxine (B). The corresponding DNA was labelled by Hoechst 33342 (C and  
445 D). Quantification of CTSB activity was evaluated by measuring the fluorescence intensity (Fig.  
446 1E). Total number of COCs used is 59. CTSB activity was higher in IVM oocytes matured  
447 without pyridoxine (F) than those matured with pyridoxine (G). Corresponding quantification of  
448 CTSB activity (H). PN, pyridoxine. Total number of oocytes used is 63. The experiments were

449 replicated 3 times. Original magnification is 100X. The data are expressed as the means  $\pm$  SEM.;  
450 \* P < 0.05, \*\*\* P < 0.001.

451 **Figure 2 Effect of pyridoxine treatment during IVM on the percentage of TUNNEL**  
452 **positive cells and *CTSB* expression in day 8 blastocyst.**

453 Number of TUNEL positive cells was higher in the blastocysts from oocytes matured without  
454 250  $\mu$ M pyridoxine (A) than those matured with pyridoxine (B). The corresponding DNA was  
455 labelled (C and D). Corresponding quantification of the percentage of TUNEL positive cells (E).  
456 This experiment was replicated 3 times and total number of embryos used is 43. *CTSB*  
457 expression was significantly lower in the resultant blastocysts from oocytes matured with  
458 pyridoxine than control group (B). PN, pyridoxine. This experiment was replicated 3 times. The  
459 data are expressed as the means  $\pm$  SEM.; \* P < 0.05.

460 **Figure S1 Effect of different concentrations of pyridoxine during IVM on cleavage and**  
461 **blastocyst rates.**

462 Bovine COCs were matured for 24 h in maturation medium supplemented with different  
463 concentrations (0, 100, 250 and 500  $\mu$ M) of pyridoxine to evaluate the dose-dependent effect.  
464 IVM COCs were fertilized prior to IVC for 8 days. Highest blastocyst rate was achieved by  
465 using 250  $\mu$ M pyridoxine (PN). However, cleavage rates showed no significant difference  
466 among the concentrations. This experiment was replicated 4 times and the total number of  
467 oocytes was 613. The data are expressed as the means  $\pm$  SEM.; \* P < 0.05.

468

469 **Table 1:** List of oligonucleotide primers used for RT-PCR

470

Target gene	Gene bank accession number	Primer sequence (5' -3')	Product length (bp)
<i>CTSB</i>	NM_174031.2	CACTTGGAAGGCTGGACACA GCATCGAAGCTTTCAGGCAG	141
<i>H2AFZ</i>	NM_174809.2	AGAGCCGGTTTGCAGTTCCCG TACTCCAGGATGGCTGCGCTGT	116

471

472

473 **Table 2:** Effect of pyridoxine on the developmental competence of bovine oocytes

Treatment	No. of replicates	Cleavage rate (%)	Blastocyst rate (%)	Hatched Blastocysts (%)
Control	6	50.9 ± 7.0 <sup>a</sup>	17.6 ± 3.1 <sup>a</sup>	8.3 ± 2.3 <sup>a</sup>
250 µM PN	6	69.3 ± 5.4 <sup>a</sup>	32.4 ± 4.5 <sup>b</sup>	21.4 ± 4.2 <sup>b</sup>

474

475 Total number of putative zygotes used was 299. PN: pyridoxine. Values with different letters  
476 across treatments differ significantly. The data are expressed as the means ± SEM.; P < 0.05.

477

478



479 **Table 3:** Effect of pyridoxine on cell number and allocation of day 8 blastocysts

Treatment	No. of Blastocyst examined	No. of cells in		
		ICM	TE	Whole embryo
Control	20	33.0 ± 0.7 <sup>a</sup>	86.9 ± 1.8 <sup>a</sup>	119.9 ± 2 <sup>a</sup>
250 μM PN	21	31.7 ± 0.7 <sup>b</sup>	106.1 ± 2.4 <sup>b</sup>	137.8 ± 2.5 <sup>b</sup>

480 PN: pyridoxine, ICM: inner cell mass, TE: trophoctoderm and TCN: total cell number. Values with  
 481 different letters across treatments differ significantly. The data are expressed as the means ± SEM.; P <  
 482 0.05.

483

484

485

486 Fig. 1:

487

488

489

490

491


492

493

494

495

496



497

498

499



500

501

502


503

504





505 Fig: 2

506




507

508



509 Fig. S1:



510